Eli Lilly and Company (LLY) impressed investors with its robust second-quarter 2024 results on Aug 8. Shares jumped 9.5% following the earnings release and an additional 5.5% the next day. The pharmaceutical giant beat on both the top and bottom lines and raised its outlook for 2024, fueled by the strong demand for its diabetes and weight-loss products — Mounjaro and Zepbound. Impressed by blowout earnings, several analysts raised their target price on the stock (read: ETFs to Profit from the Weight Loss Dr ...